Structure Therapeutics
GPCR
16.13
-0.99
-5.78%
Structure Therapeutics
US · GPCR
#2815 by market cap
Listed 2023
16.13
-0.99
-5.78%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:30
Recent news
-
Company notice
SIHUAN PHARM: VOLUNTARY ANNOUNCEMENT-SIHUAN PHARMACEUTICAL SIGNS COOPERATION AGREEMENT WITH U.S.-BASED ABALONE BIO TO JOINTLY DEVELOP A NEW-GENERATION INNOVATIVE THERAPY FOR WEIGHT LOSS AND MUSCLE GAIN, FURTHER DEEPENING ITS LAYOUT IN THE GPCR TARGET FIELDHKEX · 2025/10/30
-
Rating change
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $111Market Newswire · 2026/8/8
-
Company notice
Nxera Pharma: Nxera Pharma Licenses GPCR-targeted Program to Newly Founded Spin-out CompanyJPX · 2026/2/12
-
Company notice
XTALPI: VOLUNTARY ANNOUNCEMENTSTRATEGIC PARTNERSHIP WITH A LEADING BIOPHARMA COMPANYTO DEVELOP ORAL SMALL MOLECULE THERAPEUTICSFOR A GPCR TARGET, WITH A TOTAL POTENTIAL DEAL VALUE OFOVER US$400 MILLIONHKEX · 2026/6/9
-
CCORF Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Cuts Target Price to $107Market Newswire · 2026/11/10
-
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/11/12
-
Rating change
Morgan Stanley Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $126Market Newswire · 2026/8/10
-
Rating change
Canaccord Genuity Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/9/9
-
Rating change
CCORF Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $111Market Newswire · 2026/9/9
-
Company notice
Nxera Pharma: Nxera Pharma Announces Progress of Out Licensing of GPCR-targeted Program and Participation in Series A FinancingJPX · 2026/5/11
-
Rating change
Analysts Offer Insights on Healthcare Companies: Structure Therapeutics, Inc. Sponsored ADR (GPCR), Belite Bio, Inc. ADR (BLTE) and BridgeBio Oncology Therapeutics (BBOT)TipRanks · 2026/9/9
-
Rating change
Analysts Have Conflicting Sentiments on These Healthcare Companies: Oculis Holding (OCS), Stevanato Group (STVN) and Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/8/10
-
Citi Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $97Market Newswire · 2026/8/10
-
Stifel Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $90Market Newswire · 2026/11/10
-
Rating change
J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Announces Target Price $100Market Newswire · 2026/8/17
-
Rating change
Analysts Are Bullish on These Healthcare Stocks: EnGene Holdings (ENGN), Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/9/9
-
Company notice
Nxera Pharma: Announcement Regarding Progress on the License Agreement for the GPCR-Targeted Program and Partial Investment in the Series A FinancingJPX · 2026/5/11
-
Piper Sandler Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $93Market Newswire · 2026/11/10
-
Rating change
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $70 to $125Market Newswire · 2026/9/9
-
Rating change
Jefferies Remains a Buy on Structure Therapeutics, Inc. Sponsored ADR (GPCR)TipRanks · 2026/8/8
-
Rating change
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Cuts Target Price to $70Market Newswire · 2026/6/11
-
H.C. Wainwright Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $70Market Newswire · 2026/9/9
-
Rating change
J.P. Morgan Maintains Structure Therapeutics(GPCR.US) With Buy RatingMarket Newswire · 2026/6/9
-
Rating change
A Quick Look at Today's Ratings for Structure Therapeutics(GPCR.US), With a Forecast Between $97 to $145Market Newswire · 2026/8/7
-
Rating change
Cantor Fitzgerald Maintains Structure Therapeutics(GPCR.US) With Buy Rating, Maintains Target Price $101Market Newswire · 2026/6/8
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Structure Therapeutics discussion 0 comments